Search results for "Immunization"
New COVID-19 vaccines tested, authorization changes in progress for existing vaccines
The FDA further limited use of the Johnson & Johnson (Janssen) vaccine and scheduled advisory committee meetings on other vaccine questions. Two non-mRNA vaccines showed effectiveness, and other studies looked at antibody prevalence, home test accuracy, and long-term symptoms.
https://immattersacp.org/weekly/archives/2022/05/10/2.htm
10 May 2022
Details on second mRNA COVID-19 vaccine boosters
This column reviews details on recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2022/05/details-on-second-mrna-covid-19-vaccine-boosters.htm
1 May 2022
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://immattersacp.org/archives/2022/05/latest-updates-on-acps-priorities-initiatives.htm
1 May 2022
Perioperative medicine changed in the pandemic
In the face of a lack of guidance on perioperative medicine during the COVID-19 pandemic, many hospitals are developing their own guidelines on timing of surgery after infection in vaccinated patients.
https://immattersacp.org/archives/2022/05/perioperative-medicine-changed-in-the-pandemic.htm
1 May 2022
Fourth vaccine dose 62% effective against severe COVID-19 in month after receipt
Retrospective data from Israel showed that in people ages 60 years and older, an additional booster dose of the Pfizer-BioNTech COVID-19 vaccine was 55% effective against symptomatic disease and 68% effective against hospitalization.
https://immattersacp.org/weekly/archives/2022/04/19/4.htm
19 Apr 2022
Higher risk for DVT, PE, bleeding seen after COVID-19; long-term risk for VTE recurrence may be low
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
https://immattersacp.org/weekly/archives/2022/04/12/2.htm
12 Apr 2022
Hepatitis B vaccine now recommended for adults ages 19 through 59 years
The Advisory Committee on Immunization Practices has changed its guidance to encourage clinicians to offer the vaccine to adult patients, rather than target those with risk factors or wait for it to be requested.
https://immattersacp.org/weekly/archives/2022/04/05/1.htm
5 Apr 2022
Latest pandemic research looks at persistent symptoms of COVID-19, rise in alcohol deaths
More than half of patients with mild COVID-19 reported symptoms months later in one study, while another found psychiatric and neurologic consequences were similar in ICU survivors with and without COVID-19. Other research looked at the rise in alcohol-related deaths and the safety of vaccination during pregnancy.
https://immattersacp.org/weekly/archives/2022/03/29/4.htm
29 Mar 2022
Fourth doses, stealth variant, rapid tests focus of latest COVID-19 research
A fourth vaccine dose increased antibodies but didn't significantly reduce infections in an Israeli study. Antibody response is similar with the stealth variant and with the original omicron variant, a small study showed. Other research found that a rapid antigen test caught most omicron infections, and the vaccines weren't associated with neurological conditions.
https://immattersacp.org/weekly/archives/2022/03/22/4.htm
22 Mar 2022
Two studies show effectiveness of mRNA boosters against omicron variant
Other recent research on COVID-19 revealed the high transmissibility of the omicron stealth variant and changes in the brain after SARS-CoV-2 infection.
https://immattersacp.org/weekly/archives/2022/03/15/5.htm
15 Mar 2022